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CLINICAL TRIALS
Can We Stop Mass Drug Administration
Prior to 3 Annual Rounds in Communities
With Low Prevalence of Trachoma?
PRET Ziada Trial Results
Jithin Yohannan, BA; Beatriz Munoz, MS; Harran Mkocha, BS; Charlotte A. Gaydos, PhD;
Robin Bailey, MD, PhD; Thomas A. Lietman, MD; Thomas Quinn, MD; Sheila K. West, PhD
Importance: The World Health Organization recom-
mends at least 3 annual mass drug administrations
(MDAs) of azithromycin in places where the prevalence
of follicular trachoma (FT) is greater than 10%. How-
ever, stopping MDA prior to 3 rounds, if monitoring in-
dicates an absence of infection with Chlamydia tracho-
matis even if FT persists, may be more cost-effective.
Objective: To determine the prevalence of infection in
communities randomized to 3 rounds of annual MDAs
with azithromycin comparedwith communities random-
ized to a stopping rule, where MDA could cease if the
infection rate was low.
Design: A 1:1 community randomized trial comparing
usual care with a cessation rule. The Partnership for the
Rapid Elimination of Trachoma–Ziada Trial was con-
ducted from February 1, 2010, through September 1,
2011.
Setting: Sixteen communities in Tanzania with tra-
choma prevalence rates between 10% and 20%.
Participants: A total of 100 children aged 5 years or
younger randomly drawn from each community. Chil-
dren had to reside in an eligible community, have no ocu-
lar condition that prevented trachoma grading or ocular
specimen collection, and have a guardianwho could pro-
vide consent for participation.
Interventions: Cessation of MDA with azithromycin
if the community had no infection in their sample at 6
months or 18 months.
Main Outcome Measure: The prevalence of C tra-
chomatis at 18 months.
Results:None of the intervention communities met cri-
teria to stop MDA based on the 6-month or 18-month
survey; all, as well as the usual care communities, were
scheduled for a third MDA round. There was no differ-
ence in infection (2.9%vs 4.7%; P=.25) between the usual
care and cessation rule communities at 18 months.
Conclusions and Relevance: In this setting, commu-
nities with low (10%-20%) initial prevalence of active tra-
choma did not haveMDA stopped before 3 annual rounds
on the basis of monitoring for infection. Infection with
C trachomatis in communitieswith average trachoma rates
at 12% to 13% cannot be eliminated before 3 rounds of
MDA with azithromycin.
Trial Registration: clinicaltrials.gov Identifier:
NCT00792922.
JAMA Ophthalmol. 2013;131(4):431-436.
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T RACHOMA IS THE LEADINGinfectious cause of blind-ness in the world.1 It is theresult of repeated infec-tion with Chlamydia tra-
chomatis, which result in inflammation,
scarring of the conjunctiva, entropion, and
trichiasis, with the blinding sequelae of
corneal opacification and visual impair-
ment.2 Trachoma disproportionately af-
fects the poorest parts of the world and
contributes to an ongoing cycle of disabil-
ity and economic deprivation.
The World Health Organization
(WHO)has recommended a 4-pronged ap-
proach to trachoma elimination called
SAFE (Surgery to repair inturned eye-
lashes, mass administration of Antibiot-
ics to reduce the pool ofC trachomatis, Fa-
cial cleanliness to reduce transmission
frommucosal secretions andEnvironmen-
tal improvements to interrupt transmis-
sion and prevent reemergence of infec-
tion). In communities where clinical
trachoma (follicular trachoma [FT]) preva-
lence is greater than 10% in children aged
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1 to 9 years, theWHO recommends annual community-
wide mass drug administrations (MDAs) for at least 3
years, with coverage of at least 80% of the population,
followed by an impact survey.3 If the survey indicates a
prevalence of active trachoma of less than 5%, then an-
tibiotic administration can be discontinued. The most
widely used antibiotic is azithromycin, a single oral dose
at 20 mg/kg up to 1 g. Topical tetracycline ointment has
also been used, applied twice a day for 4 to 6 weeks.
However, several studies have shown that clinical signs
of trachoma can persist, even if there is no infection.4-7
Relying on clinical signs of trachoma for treatment de-
cisions may result in unnecessary treatment of commu-
nities where infection is virtually eliminated and only re-
sidual signs are present in the sample surveyed. Yet, in
some communities, even low rates of active trachoma are
associated with the presence of C trachomatis infection.8
Therefore, using a test for infection might have merit in
deciding whether MDA can be stopped. It is still unclear
howmany rounds of annual MDA are needed to achieve
the goal of less than 5% trachoma prevalence or even sus-
tained low prevalence of infection. Studies of commu-
nities in Tanzania with prevalence rates of trachoma of
more than 50%pretreatment suggest thatmultiple rounds
(more than 7 years) ofmass annual treatmentmay be nec-
essary.9,10 However, in one Tanzanian community with
20% prevalence of trachoma, as measured in all resi-
dents in a district with very little trachoma, a single round
of MDA with high coverage (95%) plus treating cases
with topical tetracycline was enough to virtually elimi-
nate infection.11 Finally, in Gambian communities with
an average of 8% trachoma prevalence (range, 3%-
24%), trachoma elimination was feasible with 1 round
of treatment.5,12
Such data suggest that in low prevalence communi-
ties (between 10% and 20%) and with delivery of MDA
at high coverage, 3 annual rounds of MDA may be un-
necessary. However, these data also suggest that the ex-
pectation that 1 round of MDAmay eliminate trachoma
in all low-prevalence settings might be unrealistic. The
results from Gambian communities where trachoma
prevalence was greater than 10%12 but in districts at the
tail end of eliminationmay not be the same as results from
other communities with a prevalence close to 10% that
are at the vanguard of elimination efforts in higher tra-
choma prevalence districts.
Wehypothesized that, in communitieswhere the start-
ing prevalence of trachoma was estimated between 10%
and 20%, less than 3 rounds of MDA would be needed
to achieve an infection rate of less than 5% in children
aged5 years or younger. Furthermore, where communi-
ties achieved an estimated prevalence of infection of less
than 5% (regardless of the status of clinical signs), we
hypothesized that the community could ceasemass treat-
ment without reemergence of infection.
METHODS
OVERVIEW
To test these hypotheses, we conducted a community-
randomized trial in Kongwa, Tanzania, where 16 communi-
ties were randomized in a 1:1 design to 2 different annualMDA
strategies: yearlymass treatment for 3 years (usual care) vs yearly
mass treatment each year if warranted by C trachomatis infec-
tion prevalence greater than 5%; otherwise, the MDA would
cease for communities in this arm and the community would
be monitored for reemergent infection (cessation rule). This
cutoff was chosen based on a previous study that showed that
when infection averaged greater than 5% after treatment, in-
fection was likely to return.13
The trial was conducted between February 2010 and Sep-
tember 2011. Communities in Kongwa district were eligible for
the study if they met the following criteria (Figure 1):
1. Had an estimated prevalence of FT between 10% and 20%
among children aged 5 years or younger based on preliminary
surveys carried out prior to the baseline survey.
2. Had not been treated in the previous 3 years.
3. Had fewer than 5000 persons.
4. Had leadership approval for participation.
Sixteen communitiesmet the eligibility criteria, and all were
randomized. Prior to participation, community leaders pro-
vided consent to overall community involvement in the study.
To participate in the study as a sentinel child, the following cri-
teria had to be met:
1. Be aged 5 years or younger at the time of census.
2. Resided in an eligible community.
3. Had no ocular condition that prevented trachoma grad-
ing or ocular specimen collection.
4. Had an identifiable guardian who could provide con-
sent to participate.
Individual written consent was obtained before all surveys.
All procedures and protocols were approved by the Johns Hop-
Villages in Kongwa District
assessed for eligibility
66
Were excluded50
Had prevalence of
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20
Had prevalence of
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7
4
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1
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8
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0
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8
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Figure 1. Consort diagram of the design and characteristics of the
Partnership for the Rapid Elimination of Trachoma–Ziada Trial. The usual
care arm received 3 rounds of MDAs, while the cessation rule group received
MDA at baseline and thereafter only if infection prevalence was greater than
0% at the 6-month or 18-month follow-up visit.
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kinsMedical Institutions institutional reviewboard and the Tan-
zania National Institute for Medical Research.
INTERVENTION
The intervention was the planned cessation of MDA after 1 or
2 rounds, if the prevalence of infection declined to less than
5% in the community as estimated at the 6-month and 18-
month surveys. Theworking definition of less than 5%was con-
servative, based on the random sample of 100 sentinel chil-
dren. If no children in the sample had infection, then the upper
confidence limit of the estimate of infection was less than 5%.
Azithromycin, 20 mg/kg, was provided to all residents older
than age 6 months in all communities, and topical tetracycline
was offered to all children 6months of age and younger. Treat-
ment was provided by trained community residents super-
vised by our research staff at several community locations (for
details about MDA and antibiotic coverage monitoring, see the
eAppendix, http://www.jamaophth.com).
OUTCOME MEASURES
The outcome measure was the prevalence of infection with C
trachomatis in the communities. The comparison was the in-
fection rates in the communities in the cessation rule arm, pre-
suming they had stopped MDA, with infection in the commu-
nities in the usual care arm,which had ongoingMDA.However,
no communities in the cessation rule arm met the criteria at
either the 6-month or 18-month survey points, and the com-
munities randomized to the usual care arm would receive 3
rounds of MDA in any case, thus all communities in both arms
proceeded to 3 rounds of MDA. After viewing the 18-month
data, the data and safety monitoring committee ended the trial
on the basis of futility that MDA in the communities in the ces-
sation rule arm would not be stopped and all communities in
the trial would receive 3 annual MDAs.
RANDOMIZATION SCHEME
The 16 eligible villages were randomized using a constrained
randomization scheme of 1:1 to each arm of the trial. The like-
lihood of unbalanced randomization was reduced by balanc-
ing each arm on baseline trachoma prevalence.14 In each com-
munity, 100 children were randomly selected for the surveys
based on the census list and using a simple random number
assignment in Access (Microsoft).
SAMPLE SIZE DETERMINATION
We determined sample size by using a sample size formula for
a 2-sample t test15:
Herem(x,k) is the cumulative distribution function of the
t distribution,  is the significant level, 1- is power,  is the
effect size between groups, n is the number of communities nec-
essary in each group, and  is the estimated standard devia-
tion. Eight communities in each arm were required to test the
null hypothesis that the prevalence of infection at 36 months
in the cessation group was not worse than in the control group
by more than 8% (=0.08), with a 2-sided  of 0.05, power
(1-) of 0.8, and estimated standard deviation of 4% (=0.04).
The 8% margin was based on clinical considerations; reemer-
gence rates were reported elsewhere.13
MASKING: STUDY METHODS
Census Prior to Each Treatment Round
The study team performed a complete census and census up-
date of all households in the study community. The methods
are described in detail elsewhere16 and in the eAppendix.
Surveys
At each survey visit, trained graders performed clinical assess-
ment for trachoma by examination of the upper tarsal plate with
a2.5-timemagnifying loopandusingWHOstandards for thepres-
ence or absence of FT or intense inflammatory trachoma. To es-
tablish infectionwithC trachomatis, sampleswere obtainedusing
Dacron swabs from the conjunctiva of the right eye, taking de-
tailed precautions to avoid contamination. The swabswere placed
in a tube, kept cold, and sent within 30 days to the Johns Hop-
kins International Chlamydia Laboratory for polymerase chain
reaction analysis. The validity of polymerase chain reaction re-
sults was confirmed using positive and negative control subjects
in every sample run.Details of fieldmethods andpolymerase chain
reaction testing are described in the eAppendix. Sampleswere re-
tested if the results were equivocal; samples were called positive
if results were positive on retest, or negative if results were nega-
tive or equivocal on retest.
Additionally, at each survey visit, sentinel children were as-
sessed for facial cleanliness based on the presence of at least 1
of the following signs17: (1) ocular discharge on the eyelashes
or lids; (2) nasal discharge on the nares, cheeks, or lips; and
(3) flies landed on the face during a 3-second observation.
STATISTICAL ANALYSES
This study was analyzed on an intention to treat basis as of the
18-month survey. The communities were analyzed according
to their randomization assignment, regardless of the fact that
those in the cessation rule arm had equal numbers of MDAs to
the usual care arm.
Baseline characteristics of communities were analyzed by
randomization arm using mean values obtained for each arm
by averaging the community mean values. P values were cal-
culated using the Wilcoxon rank-sum test.
Plots were made showing changes in FT and C trachomatis
infection over time in each village and for the mean of the vil-
lages in each arm. P values were calculated using the Wil-
coxon rank-sum test to check for significant difference in FT
orC trachomatis infection between arms at 18months.Wemod-
eled community-level prevalence of trachoma and C tracho-
matis infection on a square-root-transformed scale to stabilize
the variance. Multiple linear regression fitted with the ordinal
least-squares method was used to model the outcome of the
square root of 18-month prevalence, testing for the interven-
tion and adjusting for the baseline prevalence. The statistical
analysis was conducted using R version 2.14.0 (The R Foun-
dation for Statistical Computing).
RESULTS
There were no significant differences in baseline char-
acteristics between the 2 randomization arms (Table 1).
Therewas no difference in antibiotic coverage in either
arm at baseline or 12 months (Table 1). Average cover-
age was greater than 80% in both rounds, although lower
in the second round. Antibiotic coverage was measured
ψ2n−2 tα/2,2n−2 |δ|√n
σ√2 = |β
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by recording direct observation of ingestion of azithro-
mycin in a census book.
Overall, the prevalence of FT and infection declined
during the 18-month study in both groups (Figure 2).
At baseline, C trachomatis infection rates were 5% and
6% in the usual care and cessation arms, respectively.
After baseline antibiotic treatment, infection declined to
3% at 6 months in both groups; none of the communi-
ties in the cessation rule arm met the rule, so all pro-
ceeded to the second round of MDA. By 18 months,
infection rates were 3% and 5% in the usual care and
cessation groups, respectively. No community in the
cessation rule arm met the rule at 18 months, so all pro-
ceeded to the third round of MDA. There were no sta-
tistically significant differences in infection between the
groups at any point.
The prevalence rates of FT at baseline were 12% and
13% in the usual care arm and cessation rule arm, re-
spectively; after antibiotic treatment, they declined to ap-
proximately 8% in both groups at 6months. At 6months,
13 of the 16 communities had a prevalence of FT less than
10%. By 18 months, the prevalence of FT was 7% in the
usual care arm and 9% in the cessation rule arm. There
were no significant differences in FT prevalence be-
tween the groups at any time during the study.
Table 2 presents the intent to treat model adjusted
for baseline prevalence. There were no significant dif-
ferences at 18 months in either infection or active tra-
choma. There was no effect of increasing coverage. Nei-
ther baseline infection nor trachoma predicted infection
or trachoma prevalence in these communities at 18
months (Table 3).
COMMENT
The results of this study demonstrate that in Kongwa dis-
trict, where the overall prevalence of active trachoma in
children ages 5 years and youngerwas estimated at greater
than 20% at baseline, communities with a starting preva-
lence of active trachoma in this age group averaged close
to 10% still required at least 3 rounds of MDA, and none
could be stopped early based on a stopping rule of in-
fection of less than 5%.
We note that after 1 round of MDA, the average tra-
choma prevalence in both arms of the trial had fallen to
less than 10%. However, all but 2 of the communities still
had at least 1% and up to 8% infection at 6 months. At
18 months (6 months after the second round of MDA),
5 of the 16 communities were at greater than 10% preva-
Table 1. Baseline Characteristics of Communities and Antibiotic Coverage in the 2 Study Groups
Characteristic
Group, Mean (SD)
P ValueaUsual Care Cessation Rule
Population size, No. (%) 1140 (390) 1121 (255) .96
Average duration of education of household head, y 4.0 (0.7) 3.9 (0.4) .51
Houses 30 min from water, % 61.6 (17.9) 58.4 (22.7) .80
Houses with latrine, % 68.3 (9.5) 67.5 (14.6) .88
Sentinel children with clean faces, % 57.5 (7.7) 54.8 (14.2) .40
Prevalence of FT 12.9 (3.3) 11.5 (3.5) .46
Prevalence of Chlamydia trachomatis 5.4 (3.5) 6.4 (2.8) .46
Baseline antibiotic coverage 89.6 (5.9) 94.2 (5.0) .13
12-mo antibiotic coverage 82.7 (7.4) 88.9 (5.4) .13
Abbreviation: FT, follicular trachoma.
aP values were calculated using the Wilcoxon rank-sum test for nonparametric data.
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Figure 2. Graphs indicating infection/disease rates in villages over time.
A, Graph shows the prevalence of Chlamydia trachomatis infection over time
in the usual care and cessation rule arms. The dashed lines indicate the
mean prevalence in each arm, and the thin lines indicate community-level
prevalence. B, Graph shows the prevalence of follicular trachoma over time
in the usual care and cessation rule arms. The dashed lines indicate the
mean prevalence in each arm, and the thin lines indicate community-level
prevalence.
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lence of FT in the age group 5 years and younger, even
though the average prevalence of FT was less than 10%.
Based on the presence of infection, all the communities
randomized to the cessation rule proceeded to the third
round of MDA.
We believe our data show the importance of the wider
geographic construct to be considered when evaluating
even subdistricts for potential cessation of antibiotics. Un-
like the experience with villages in Gambia,5,12 2 rounds
of MDA with high coverage were not sufficient to stop
MDAbased on our cessation rule. The entire Kongwa dis-
trict, where the trachoma rate is greater than 20%, is being
treated along with these communities; thus, it is un-
likely that migration from neighboring communities is
a major cause of maintaining infection in this setting, al-
though we cannot rule out migration from communi-
ties outside the district. There were some communities
where, even after a second round of MDA, infection ap-
peared to increase at 18months. Notably, one village was
an outlier, with 13%prevalence of infection at 18months,
where the rest of the 15 villages were at 7% or lower.We
have no explanation for this spike, and the nearest neigh-
boring communities enrolled in the trial had 18-month
infection rates at 1% and 4%. Antibiotic coverage at 12
months was 80% in this particular village, thus, low cov-
erage is an unlikely explanation.
We do not feel that the antibiotic coverage would ex-
plain the disappointing slow decline in infection, as all
communities had coverage greater than 80%, specifi-
cally in children aged younger than 10 years at baseline,
and only 1 community had less than 80% (71%) for the
second round. Treatment verification showed high con-
cordance with observed treatment as well. In a model of
infection at 18 months, we examined the relationship of
infection to average treatment coverage, and it was not
significantly related, suggesting there was no difference
within the range of coverage we observed. Mean antibi-
otic coveragewas nonsignificantly associatedwith a lower
18-month infection prevalence, suggesting that cover-
age may be an important factor in eliminating infection.
However, our studywas not powered to answer this ques-
tion.Moreover, while there is evidence thatmissingMDA
does not occur at random,18 there is no evidence thatmiss-
ingMDA is related to infection status, suggesting that chil-
drenwith infectionwere not preferentiallymissed by treat-
ment.We also noted data that suggest it takes more than
6 months for infection to spread outside the house-
hold,19 thus, even if there was any differential coverage,
it is unlikely to explain how infection increased in some
communities within 6 months after MDA. Our coverage
was similar to that of Burton et al5,12 in the Gambian vil-
lages where 1 round was sufficient to stop infection and
reemergence did not occur.
We chose a very conservative cessation rule, with a
working definition of no infection in the sentinel sample
of 100 children. If we had chosen a less-strict guideline,
we may have been able to stop MDA earlier. However,
there are no data to guide the selection of a stopping rule
based on infection or a specific age group, and we rea-
soned that if the Gambian villages could drop infection
to less than 5% and have no reemergence, then our guide-
line was reasonable. Others have shown that even with
almost no infection in communities, once antibiotic pres-
sure is removed, reemergence does occur.20 We suggest
that these data support a viewpoint wider than a com-
munity when considering trachoma status and stopping
MDA, in line with WHO guidelines on the assessment
at district level. In Gambia, when the last few remaining
villages are being treated, then possible acceleration to
zero infection with 1 round of MDA may be reasonable.
However, low-prevalence communities in a district like
Kongwa, which on average has a trachoma rate esti-
mated at greater than 20%, cannot be singled out andwill
need at least the full 3 rounds of MDA even with high
coverage.
In conclusion, we found that using a rule for cessa-
tion of MDA based on infection status did not change
the frequency of treatment, which, based on clinical
assessment, was 3 rounds of MDA. Moreover, we
found that in our low-prevalence communities (aver-
age FT at baseline of 12%), 2 rounds of MDA were not
sufficient to reduce infection to zero. The fact that
these communities were at the low end of baseline
prevalence in a district with overall higher rates of tra-
choma suggests the wisdom of treating a wide geo-
graphic area for at least 3 rounds before impact sur-
veys, and not presuming that subdistricts on their own
can be stopped if the wider district-level prevalence
supports mass treatment.
Submitted for Publication: October 1, 2012; final revi-
sion received November 5, 2012; accepted November 8,
2012.
Published Online: February 7, 2013. doi:10.1001
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Table 2. Multivariate Linear Model of Infection
and Follicular Trachoma Prevalence at 18 Months
Predicted by Randomization Group
and Baseline Infection or Trachoma
Characteristic  Coefficient (95% CI) P Value
Predicting Infection
Cessation rule arm 0.06 (0.03 to 0.16) .22
Baseline infection, square root 0.02 (0.76 to 0.72) .96
Predicting Follicular Trachoma
Cessation rule arm 0.07 (0.01 to .15) .09
Baseline trachoma, square root 0.66 (0.13 to 1.45) .12
Table 3. Multivariate Linear Model of Infection
and Follicular Trachoma Prevalence at 18 Months
Predicted by 12-Month Antibiotic Coverage
and Baseline Infection or Trachoma
Characteristic  Coefficient (95% CI) P Value
Predicting Infection
Mean antibiotic coverage 0.34 (1.42 to 0.75) .50
Baseline infection, square root 0.21 (0.66 to 1.08) .64
Predicting Follicular Trachoma
Mean antibiotic coverage 0.29 (0.50 to 1.08) .49
Baseline trachoma, square root 0.46 (0.40 to 1.31) .31
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